Table Info

Table 1.

Patient characteristics

Characteristics	Patient
N (%)	60 (100)
Age, median, years (range)	56 (36–73)
Sarcomatoid RCC, N (%)	11 (18.3)
Organs with metastases, N (%)
1 ≥ 2	6 (10) 54 (90)
Sites of metastases, N (%)
lungs lymph nodes liver bones soft tissue adrenal brain	40 (67) 40 (67) 20 (33) 9 (15) 8 (13) 7 (12) 2 (3)
Tumor thrombus, N (%)	4 (7)
ECOG PS, N (%)
0 1 2 3	6 (10) 39 (65) 12 (20) 3 (5)
History of nephrectomy, N (%)
Yes No	52 (87) 8 (13)
IMDC risk, N (%)
Intermediate Poor	28 (47) 32 (53)

RCC: renal cell carcinoma; ECOG PS: Eastern Cooperative Oncology Group Performance Status; IMDC: International Metastatic RCC Database Consortium

Declarations

Acknowledgments

Prior presentation: presented in part at the ESMO Asia Meeting 2024, Singapore; the relevant research abstract included some of the results and was published as the conference abstract in Annals of Oncology (https://www.annalsofoncology.org/article/S0923-7534(24)04371-0/fulltext).

Author contributions

AS, DD, MM, AV, RO, IU, GM, and MG: Conceptualization, Data curation, Investigation, Writing—review & editing. IT: Conceptualization, Data curation, Formal analysis, Investigation, Project administration, Writing—review & editing, Writing—original draft.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

This study was approved by the Institutional Ethics Committee (Bureau for Cancer Research, Moscow) with Project Approval No. KCRB12012023-01.

Consent to participate

The informed consent to participate in the study was obtained from all participants.

Consent to publication

Not applicable.

Availability of data and materials

The raw data are not available due to confidentiality.

Funding

Not applicable.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Tsimafeyeu I, Zolotareva T, Varlamov S, Zukov R, Petkau V, Mazhbich M, et al. Five-year Survival of Patients With Metastatic Renal Cell Carcinoma in the Russian Federation: Results From the RENSUR5 Registry. Clin Genitourin Cancer. 2017;15:e1069–72. [DOI] [PubMed]

Tsimafeyeu I, Shatkovskaya O, Krasny S, Nurgaliev N, Varlamov I, Petkau V, et al. Overall survival in patients with metastatic renal cell carcinoma in Russia, Kazakhstan, and Belarus: a report from the RENSUR3 registry. Cancer Rep (Hoboken). 2021;4:e1331. [DOI] [PubMed] [PMC]

Barragan-Carrillo R, Saad E, Saliby R, Sun M, Albiges L, Bex A, et al. First and Second-line Treatments in Metastatic Renal Cell Carcinoma. Eur Urol. 2025;87:143–54. [DOI] [PubMed]

Motzer RJ, Porta C, Eto M, Hutson TE, Rha SY, Merchan JR, et al. Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma. Ann Oncol. 2025;36:375–86. [DOI] [PubMed]

Choueiri TK, Eto M, Motzer R, Giorgi UD, Buchler T, Basappa NS, et al. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Lancet Oncol. 2023;24:228–38. Erratum in: Lancet Oncol. 2023;24:e146. [DOI] [PubMed]

Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, et al.; CLEAR Trial Investigators. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. J Clin Oncol. 2024;42:1222–8. [DOI] [PubMed] [PMC]

Hara T, Suzuki K, Okamura Y, Chiba K, Sato R, Matsushita Y, et al. Efficacy and safety of lenvatinib and pembrolizumab as first-line treatment for advanced renal cell carcinoma patients: real-world experience in Japan. Int J Clin Oncol. 2024;29:1931–6. [DOI] [PubMed]

Dutcher JP, Flippot R, Fallah J, Escudier B. On the Shoulders of Giants: The Evolution of Renal Cell Carcinoma Treatment—Cytokines, Targeted Therapy, and Immunotherapy. Am Soc Clin Oncol Educ Book. 2020;40:1–18. [DOI] [PubMed]

Roskoski R Jr. Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas. Pharmacol Res. 2024;203:107181. [DOI] [PubMed]

10.

Grünwald V, Powles T, Eto M, Kopyltsov E, Rha SY, Porta C, et al. Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. Front Oncol. 2024;13:1343027. Erratum for: Front Oncol. 2023;13:1223282. [DOI] [PubMed] [PMC]